• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非接触残基对抗体亲和力的调节。

Modulation of antibody affinity by a non-contact residue.

作者信息

Schillbach J F, Near R I, Bruccoleri R E, Haber E, Jeffrey P D, Novotny J, Sheriff S, Margolies M N

机构信息

Program on Immunology, Harvard University Graduate School of Arts and Sciences, Cambridge, Massachusetts 02138.

出版信息

Protein Sci. 1993 Feb;2(2):206-14. doi: 10.1002/pro.5560020209.

DOI:10.1002/pro.5560020209
PMID:8443598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2142342/
Abstract

Antibody LB4, produced by a spontaneous variant of the murine anti-digoxin monoclonal antibody 26-10, has an affinity for digoxin two orders of magnitude lower than that of the parent antibody due to replacement of serine with phenylalanine at position 52 of the heavy chain variable region (Schildbach, J.F., Panka, D.J., Parks, D.R., et al., 1991, J. Biol. Chem. 266, 4640-4647). To examine the basis for the decreased affinity, a panel of engineered antibodies with substitutions at position 52 was created, and their affinities for digoxin were measured. The antibody affinities decreased concomitantly with increasing size of the substituted side chains, although the shape of the side chains also influenced affinity. The crystal structure of the 26-10 Fab complexed with digoxin (P.D.J., R.K. Strong, L.C. Sieker, C. Chang, R.L. Campbell, G.A. Petsko, E.H., M.N.M., & S.S., submitted for publication) shows that the serine at heavy chain position 52 is not in contact with hapten, but is adjacent to a tyrosine at heavy chain position 33 that is a contact residue. The mutant antibodies were modeled by applying a conformational search procedure to position side chains, using the 26-10 Fab crystal structure as a starting point. The results suggest that each of the substituted side chains may be accommodated within the antibody without substantial structural rearrangement, and that none of these substituted side chains are able to contact hapten. These modeling results are consistent with the substituents at position 52 having only an indirect influence upon antibody affinity.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

抗体LB4由鼠抗地高辛单克隆抗体26 - 10的自发变体产生,由于重链可变区第52位的丝氨酸被苯丙氨酸取代,其与地高辛的亲和力比亲本抗体低两个数量级(席尔德巴赫,J.F.,潘卡,D.J.,帕克斯,D.R.等,1991,《生物化学杂志》266,4640 - 4647)。为了研究亲和力降低的原因,构建了一组在第52位有取代的工程抗体,并测量了它们与地高辛的亲和力。抗体亲和力随着取代侧链尺寸的增加而相应降低,尽管侧链的形状也会影响亲和力。与地高辛复合的26 - 10 Fab的晶体结构(P.D.J.,R.K.斯特朗,L.C.西克,C.张,R.L.坎贝尔,G.A.佩茨科,E.H.,M.N.M.和S.S.,已提交发表)表明,重链第52位的丝氨酸不与半抗原接触,但与重链第33位的酪氨酸相邻,而该酪氨酸是一个接触残基。以26 - 10 Fab晶体结构为起点,通过应用构象搜索程序来定位侧链,对突变抗体进行建模。结果表明,每个取代侧链都可以在不进行大量结构重排的情况下容纳在抗体中,并且这些取代侧链都不能与半抗原接触。这些建模结果与第52位的取代基仅对抗体亲和力有间接影响一致。(摘要截短至250字)

相似文献

1
Modulation of antibody affinity by a non-contact residue.非接触残基对抗体亲和力的调节。
Protein Sci. 1993 Feb;2(2):206-14. doi: 10.1002/pro.5560020209.
2
Heavy chain position 50 is a determinant of affinity and specificity for the anti-digoxin antibody 26-10.重链第50位是抗地高辛抗体26 - 10亲和力和特异性的一个决定因素。
J Biol Chem. 1993 Oct 15;268(29):21739-47.
3
Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.单个重链残基对抗地高辛单克隆抗体特异性的贡献。
Protein Sci. 1994 May;3(5):737-49. doi: 10.1002/pro.5560030503.
4
A V kappa-J kappa junctional change in an antidigoxin recombinant antibody destroys digoxin-binding activity.抗地高辛重组抗体中Vκ-Jκ连接区的变化会破坏地高辛结合活性。
J Immunol. 1990 Oct 15;145(8):2718-24.
5
Structure and specificity of the anti-digoxin antibody 40-50.抗地高辛抗体40 - 50的结构与特异性
J Mol Biol. 1995 Apr 28;248(2):344-60. doi: 10.1016/s0022-2836(95)80055-7.
6
Altered hapten recognition by two anti-digoxin hybridoma variants due to variable region point mutations.由于可变区点突变,两种抗地高辛杂交瘤变体对半抗原的识别发生改变。
J Biol Chem. 1991 Mar 5;266(7):4640-7.
7
Modifying specificity of antidigoxin antibodies using insertional mutagenesis.利用插入诱变改变抗地高辛抗体的特异性。
Protein Sci. 2002 Dec;11(12):2899-908. doi: 10.1110/ps.0223402.
8
Phage display-selected sequences of the heavy-chain CDR3 loop of the anti-digoxin antibody 26-10 define a high affinity binding site for position 16-substituted analogs of digoxin.抗地高辛抗体26-10重链CDR3环的噬菌体展示筛选序列确定了地高辛16位取代类似物的高亲和力结合位点。
J Biol Chem. 2001 Mar 16;276(11):8149-58. doi: 10.1074/jbc.M008108200. Epub 2000 Nov 1.
9
Complementary combining site contact residue mutations of the anti-digoxin Fab 26-10 permit high affinity wild-type binding.抗地高辛Fab 26-10的互补结合位点接触残基突变允许高亲和力野生型结合。
J Biol Chem. 2002 May 10;277(19):16365-70. doi: 10.1074/jbc.M110444200. Epub 2002 Feb 19.
10
A spontaneous variant of an antidigoxin hybridoma antibody with increased affinity arises from a heavy chain signal peptide mutation.一种具有更高亲和力的抗地高辛杂交瘤抗体自发变体源自重链信号肽突变。
Mol Immunol. 1992 Apr;29(4):525-9. doi: 10.1016/0161-5890(92)90010-u.

引用本文的文献

1
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.抗体特异性的过时观念是基于结构的反向疫苗学范式的主要有害假设之一,这使其无法助力开发有效的HIV-1疫苗。
Front Immunol. 2014 Nov 18;5:593. doi: 10.3389/fimmu.2014.00593. eCollection 2014.
2
Basic research in HIV vaccinology is hampered by reductionist thinking.HIV 疫苗学的基础研究受到还原论思维的阻碍。
Front Immunol. 2012 Jul 9;3:194. doi: 10.3389/fimmu.2012.00194. eCollection 2012.
3
Closely related antibody receptors exploit fundamentally different strategies for steroid recognition.密切相关的抗体受体利用根本不同的策略进行类固醇识别。
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11725-30. doi: 10.1073/pnas.0801783105. Epub 2008 Aug 8.
4
An efficient visualization tool for the analysis of protein mutation matrices.一种用于分析蛋白质突变矩阵的高效可视化工具。
BMC Bioinformatics. 2008 Apr 28;9:218. doi: 10.1186/1471-2105-9-218.
5
26-10 Fab-digoxin complex: affinity and specificity due to surface complementarity.26 - 10 法布里片段 - 地高辛复合物:基于表面互补性的亲和力和特异性。
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10310-4. doi: 10.1073/pnas.90.21.10310.
6
Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.单个重链残基对抗地高辛单克隆抗体特异性的贡献。
Protein Sci. 1994 May;3(5):737-49. doi: 10.1002/pro.5560030503.
7
The structural repertoire of the human V kappa domain.人类Vκ结构域的结构组成
EMBO J. 1995 Sep 15;14(18):4628-38. doi: 10.1002/j.1460-2075.1995.tb00142.x.

本文引用的文献

1
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.高比放射性碘-131标记人生长激素的制备
Biochem J. 1963 Oct;89(1):114-23. doi: 10.1042/bj0890114.
2
LIGAND: a computerized analysis of ligand binding data.配体:配体结合数据的计算机化分析
Methods Enzymol. 1983;92:543-76. doi: 10.1016/0076-6879(83)92044-x.
3
High-affinity monoclonal antibodies to the cardiac glycoside, digoxin.针对强心苷地高辛的高亲和力单克隆抗体。
J Immunol. 1982 Sep;129(3):1165-72.
4
Rapid and efficient site-specific mutagenesis without phenotypic selection.无需表型筛选的快速高效位点特异性诱变。
Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92. doi: 10.1073/pnas.82.2.488.
5
Structure of proteins with single-site mutations: a minimum perturbation approach.单点突变蛋白质的结构:一种最小扰动方法。
Proc Natl Acad Sci U S A. 1985 Mar;82(6):1697-700. doi: 10.1073/pnas.82.6.1697.
6
Prediction of the folding of short polypeptide segments by uniform conformational sampling.通过统一构象采样预测短多肽片段的折叠
Biopolymers. 1987 Jan;26(1):137-68. doi: 10.1002/bip.360260114.
7
Replacing the complementarity-determining regions in a human antibody with those from a mouse.用人抗体中的互补决定区替换小鼠抗体中的互补决定区。
Nature. 1986;321(6069):522-5. doi: 10.1038/321522a0.
8
Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution.叠氮高铁肌红蛋白在1.7/1.3埃分辨率下的结构。
J Mol Biol. 1987 Sep 20;197(2):273-96. doi: 10.1016/0022-2836(87)90124-0.
9
Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies.可变区框架差异导致变异抗地高辛抗体的亲和力降低或增加。
Proc Natl Acad Sci U S A. 1988 May;85(9):3080-4. doi: 10.1073/pnas.85.9.3080.
10
Reshaping human antibodies for therapy.重塑用于治疗的人源抗体。
Nature. 1988 Mar 24;332(6162):323-7. doi: 10.1038/332323a0.